pre-IPO PHARMA

COMPANY OVERVIEW

Precision Biosciences utilize a proprietary genome editing method we call ARCUS combined with a team made up of some of the leading minds and pioneers in genome editing in an effort to overcome cancers, cure genetic diseases, and enable the development of safer, more productive food sources.


LOCATION

  • Durham, NC, USA

  • THERAPEUTIC AREAS

  • Oncology
  • Rare Diseases

  • WEBSITE

    https://precisiobiosciences.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    agent-capital f-prime-capital-partners osage-university-partners ra-capital


    PRESS RELEASES


    Jan 16, 2019

    Precision BioSciences Announces Formation of Scientific Advisory Board with Anderson, Kantarjian, Schinazi and Turtle


    Dec 20, 2018

    Precision BioSciences Appoints Rare Disease Executive Shalini Sharp to Its Board of Directors


    Dec 6, 2018

    Precision BioSciences and Durham STEM Students Lead Launch of First Genome Editing Experiment Into Space


    Nov 27, 2018

    Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy


    Nov 14, 2018

    Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement


    For More Press Releases


    Google Analytics Alternative